CD133, selectively targeting the root of cancer

Toxins

Volumn 8, Issue 6, 2016, Pages

  Schmohl, Jörg U ^a,b   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

BIKE; Cancer stem cell; CD133; Relapse; Targeted therapies

Indexed keywords

CD133 ANTIGEN; TUMOR MARKER;

ANIMAL; CANCER STEM CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

AC133 ANTIGEN; ANIMALS; BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84971260415     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8060165     Document Type: Review

References (136)

1. Bonnet, D, Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737. [CrossRef] [PubMed]
2. Cho, R.W, Clarke, M.F. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 2008, 18, 48-53. [CrossRef] [PubMed]
3. Boman, B.M, Wicha, M.S. Cancer stem cells: A step toward the cure. J. Clin. Oncol. 2008, 26, 2795-2799. [CrossRef] [PubMed]
4. Ferrandina, G, Petrillo, M, Bonanno, G, Scambia, G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13, 823-837. [CrossRef] [PubMed]
5. Shmelkov, S.V, St Clair, R, Lyden, D, Rafii, S. AC133/CD133/Prominin-1. Int. J. Biochem. Cell. Biol. 2005, 37, 715-719. [CrossRef] [PubMed]
6. Bauer, N, Fonseca, A.V, Florek, M, Freund, D, Jaszai, J, Bornhauser, M, Fargeas, C.A, Corbeil, D. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008, 188, 127-138. [CrossRef] [PubMed]
7. Ulasov, I.V, Nandi, S, Dey, M, Sonabend, A.M, Lesniak, M.S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133+ glioma stem cells to temozolomide therapy. Mol. Med. 2011, 17, 103-112. [CrossRef] [PubMed]
8. Evangelista, M, Tian, H, de Sauvage, F.J. The hedgehog signaling pathway in cancer. Clin. Cancer Res. 2006, 12, 5924-5928. [CrossRef] [PubMed]
9. Rappa, G, Fodstad, O, Lorico, A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 2008, 26, 3008-3017. [CrossRef] [PubMed]
10. Mak, A.B, Nixon, A.M, Kittanakom, S, Stewart, J.M, Chen, G.I, Curak, J, Gingras, A.C, Mazitschek, R, Neel, B.G, Stagljar, I, et al. Regulation of CD133 by HDAC6 promotes beta-catenin signaling to suppress cancer cell differentiation. Cell. Rep. 2012, 2, 951-963. [CrossRef] [PubMed]
11. Takenobu, H, Shimozato, O, Nakamura, T, Ochiai, H, Yamaguchi, Y, Ohira, M, Nakagawara, A, Kamijo, T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30, 97-105. [CrossRef] [PubMed]
12. Wu, Y.J, Wu, P.Y. CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns. Stem Cells Dev. 2009, 18, 1127-1134. [CrossRef] [PubMed]
13. Horst, D, Kriegl, L, Engel, J, Kirchner, T, Jung, A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br. J. Cancer 2008, 99, 1285-1289. [CrossRef] [PubMed]
14. Wu, B, Sun, C, Feng, F, Ge, M, Xia, L. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 2015, 34, 44. [CrossRef] [PubMed]
15. Zhong, C, Wu, J.D, Fang, M.M, Pu, L.Y. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: A meta-analysis. Tumour Biol. 2015, 36, 7623-7630. [CrossRef] [PubMed]
16. Waldron N, V.D. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies 2013, 2, 82-89. [CrossRef]
17. Finney, H.M, Akbar, A.N, Lawson, A.D. Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172, 104-113. [CrossRef] [PubMed]
18. Imai, C, Mihara, K, Andreansky, M, Nicholson, I.C, Pui, C.H, Geiger, T.L, Campana, D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18, 676-684. [CrossRef] [PubMed]
19. Grupp, S.A, Kalos, M, Barrett, D, Aplenc, R, Porter, D.L, Rheingold, S.R, Teachey, D.T, Chew, A, Hauck, B, Wright, J.F, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368, 1509-1518. [CrossRef] [PubMed]
20. Pinz, K, Liu, H, Golightly, M, Jares, A, Lan, F, Zieve, G.W, Hagag, N, Schuster, M, Firor, A.E, Jiang, X, et al. Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia 2015, 30, 701-707. [CrossRef] [PubMed]
21. Gill, S, June, C.H. Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 2015, 263, 68-89. [CrossRef] [PubMed]
22. Yuan, S.Z, Su, H. Clinical translational research of chimeric antigen receptor-T (CAR-T) cells for the treatment of relapsed and refractory B-cell lymphoma/leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014, 22, 1137-1141. [PubMed]
23. Smyth, M.J, Godfrey, D.I, Trapani, J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001, 2, 293-299. [CrossRef] [PubMed]
24. Watzl, C, Long, E.O. Exposing tumor cells to killer cell attack. Nat. Med. 2000, 6, 867-868. [CrossRef] [PubMed]
25. Pardoll, D.M. Stress, NK receptors, and immune surveillance. Science 2001, 294, 534-536. [CrossRef] [PubMed]
26. Sogn, J.A. Tumor immunology: The glass is half full. Immunity 1998, 9, 757-763. [CrossRef]
27. Chen, L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 1998, 19, 27-30. [CrossRef]
28. Dunn, G.P, Old, L.J, Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148. [CrossRef] [PubMed]
29. Lyer, K.S, Saksena, V.N. A stochastic model of the growth of cancer in cancer. Biometrics 1970, 26, 401-410.
30. Jackson, E.B, Brues, A.M. Studies on a Transplantable Embryoma of the Mouse. Cancer Res. Treat. 1941, 1, 494-498.
31. Makino, S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann. N. Y. Acad. Sci. 1956, 63, 818-830. [CrossRef] [PubMed]
32. Lapidot, T, Sirard, C, Vormoor, J, Murdoch, B, Hoang, T, Caceres-Cortes, J, Minden, M, Paterson, B, Caligiuri, M.A, Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645-648. [CrossRef] [PubMed]
33. Richardson, G.D, Robson, C.N, Lang, S.H, Neal, D.E, Maitland, N.J, Collins, A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell. Sci. 2004, 117, 3539-3545. [CrossRef] [PubMed]
34. Mehra, N, Penning, M, Maas, J, Beerepoot, L.V, van Daal, N, van Gils, C.H, Giles, R.H, Voest, E.E. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin. Cancer Res. 2006, 12, 4859-4866. [CrossRef] [PubMed]
35. Singh, S.K, Clarke, I.D, Terasaki, M, Bonn, V.E, Hawkins, C, Squire, J, Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828. [PubMed]
36. Singh, S.K, Hawkins, C, Clarke, I.D, Squire, J.A, Bayani, J, Hide, T, Henkelman, R.M, Cusimano, M.D, Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401. [CrossRef] [PubMed]
37. Ricci-Vitiani, L, Lombardi, D.G, Pilozzi, E, Biffoni, M, Todaro, M, Peschle, C, de Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115. [CrossRef] [PubMed]
38. Miki, J, Furusato, B, Li, H, Gu, Y, Takahashi, H, Egawa, S, Sesterhenn, I.A, McLeod, D.G, Srivastava, S, Rhim, J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007, 67, 3153-3161. [CrossRef] [PubMed]
39. Fang, D, Nguyen, T.K, Leishear, K, Finko, R, Kulp, A.N, Hotz, S, Van Belle, P.A, Xu, X, Elder, D.E, Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65, 9328-9337. [CrossRef] [PubMed]
40. Yang, C.H, Wang, H.L, Lin, Y.S, Kumar, K.P, Lin, H.C, Chang, C.J, Lu, C.C, Huang, T.T, Martel, J, Ojcius, D.M, et al. Identification of CD24 as a cancer stem cell marker in human nasopharyngeal carcinoma. PLoS One 2014, 9, e99412. [CrossRef] [PubMed]
41. Fillmore, C, Kuperwasser, C. Human breast cancer stem cell markers CD44 and CD24: Enriching for cells with functional properties in mice or in man? Breast Cancer Res. 2007, 9, 303. [CrossRef] [PubMed]
42. Li, C, Lee, C.J, Simeone, D.M. Identification of human pancreatic cancer stem cells. Methods Mol. Biol. 2009, 568, 161-173. [PubMed]
43. Kucia, M, Reca, R, Miekus, K, Wanzeck, J, Wojakowski, W, Janowska-Wieczorek, A, Ratajczak, J, Ratajczak, M.Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23, 879-894. [CrossRef] [PubMed]
44. Mukherjee, D, Zhao, J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 2013, 3, 46-57. [PubMed]
45. Zheng, X, Xie, Q, Li, S, Zhang, W. CXCR4-positive subset of glioma is enriched for cancer stem cells. Oncol. Res. 2011, 19, 555-561. [CrossRef] [PubMed]
46. Bertolini, G, D’Amico, L, Moro, M, Landoni, E, Perego, P, Miceli, R, Gatti, L, Andriani, F, Wong, D, Caserini, R, et al. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM—Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. Cancer Res. 2015, 75, 3636-3649. [CrossRef] [PubMed]
47. Chan, K.S, Espinosa, I, Chao, M, Wong, D, Ailles, L, Diehn, M, Gill, H, Presti, J., Jr, Chang, H.Y, van de Rijn, M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009, 106, 14016-14021. [CrossRef] [PubMed]
48. Zhang, H, Lu, H, Xiang, L, Bullen, J.W, Zhang, C, Samanta, D, Gilkes, D.M, He, J, Semenza, G.L. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc. Natl. Acad. Sci. USA 2015, 112, E6215-E6223. [CrossRef] [PubMed]
49. Du, L, Wang, H, He, L, Zhang, J, Ni, B, Wang, X, Jin, H, Cahuzac, N, Mehrpour, M, Lu, Y, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin. Cancer Res. 2008, 14, 6751-6760. [CrossRef] [PubMed]
50. Takaishi, S, Okumura, T, Tu, S, Wang, S.S, Shibata, W, Vigneshwaran, R, Gordon, S.A, Shimada, Y, Wang, T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27, 1006-1020. [CrossRef] [PubMed]
51. Zhang, S, Balch, C, Chan, M.W, Lai, H.C, Matei, D, Schilder, J.M, Yan, P.S, Huang, T.H, Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320. [CrossRef] [PubMed]
52. Gorelik, E, Lokshin, A, Levina, V. Lung cancer stem cells as a target for therapy. Anticancer Agents Med. Chem. 2010, 10, 164-171. [CrossRef] [PubMed]
53. Chen, J, Wang, J, Chen, D, Yang, J, Yang, C, Zhang, Y, Zhang, H, Dou, J. Evaluation of characteristics of CD44+ CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell. Biol. 2013, 14, 7. [CrossRef] [PubMed]
54. Lin, C.W, Liao, M.Y, Lin, W.W, Wang, Y.P, Lu, T.Y, Wu, H.C. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J. Biol. Chem. 2012, 287, 39449-39459. [CrossRef] [PubMed]
55. Baccelli, I, Schneeweiss, A, Riethdorf, S, Stenzinger, A, Schillert, A, Vogel, V, Klein, C, Saini, M, Bauerle, T, Wallwiener, M, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31, 539-544. [CrossRef] [PubMed]
56. Korkaya, H, Wicha, M.S. HER2 and breast cancer stem cells: More than meets the eye. Cancer Res. 2013, 73, 3489-3493. [CrossRef] [PubMed]
57. Ponnusamy, M.P, Seshacharyulu, P, Vaz, A, Dey, P, Batra, S.K. MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J. Ovarian Res. 2011, 4, 7. [CrossRef] [PubMed]
58. Nadal, R, Ortega, F.G, Salido, M, Lorente, J.A, Rodriguez-Rivera, M, Delgado-Rodriguez, M, Macia, M, Fernandez, A, Corominas, J.M, Garcia-Puche, J.L, et al. CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. Int. J. Cancer 2013, 133, 2398-2407. [CrossRef] [PubMed]
59. Meyer, M.J, Fleming, J.M, Lin, A.F, Hussnain, S.A, Ginsburg, E, Vonderhaar, B.K. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010, 70, 4624-4633. [CrossRef] [PubMed]
60. Catalano, V, Di Franco, S, Iovino, F, Dieli, F, Stassi, G, Todaro, M. CD133 as a target for colon cancer. Expert Opin. Ther. Targets. 2012, 16, 259-267. [CrossRef] [PubMed]
61. Shepherd, C.J, Rizzo, S, Ledaki, I, Davies, M, Brewer, D, Attard, G, de Bono, J, Hudson, D.L. Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate 2008, 68, 1007-1024. [CrossRef] [PubMed]
62. Monzani, E, Facchetti, F, Galmozzi, E, Corsini, E, Benetti, A, Cavazzin, C, Gritti, A, Piccinini, A, Porro, D, Santinami, M, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43, 935-946. [CrossRef] [PubMed]
63. Donnenberg, V.S, Landreneau, R.J, Donnenberg, A.D. Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents. J. Control. Release. 2007, 122, 385-391. [CrossRef] [PubMed]
64. Damek-Poprawa, M, Volgina, A, Korostoff, J, Sollecito, T.P, Brose, M.S, O’Malley, B.W., Jr, Akintoye, S.O, DiRienzo, J.M. Targeted inhibition of CD133+ cells in oral cancer cell lines. J. Dent. Res. 2011, 90, 638-645. [CrossRef] [PubMed]
65. Skubitz, A.P, Taras, E.P, Boylan, K.L, Waldron, N.N, Oh, S, Panoskaltsis-Mortari, A, Vallera, D.A. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol. Oncol. 2013, 130, 579-587. [CrossRef] [PubMed]
66. Immervoll, H, Hoem, D, Sakariassen, P.O, Steffensen, O.J, Molven, A. Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008, 8, 48. [CrossRef] [PubMed]
67. Maeda, S, Shinchi, H, Kurahara, H, Mataki, Y, Maemura, K, Sato, M, Natsugoe, S, Aikou, T, Takao, S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br. J. Cancer 2008, 98, 1389-1397. [CrossRef] [PubMed]
68. Ishigami, S, Ueno, S, Arigami, T, Uchikado, Y, Setoyama, T, Arima, H, Kita, Y, Kurahara, H, Okumura, H, Matsumoto, M, et al. Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res. 2010, 30, 2453-2457. [PubMed]
69. Ma, S, Chan, K.W, Hu, L, Lee, T.K, Wo, J.Y, Ng, I.O, Zheng, B.J, Guan, X.Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132, 2542-2556. [CrossRef] [PubMed]
70. Zhu, L, Gibson, P, Currle, D.S, Tong, Y, Richardson, R.J, Bayazitov, I.T, Poppleton, H, Zakharenko, S, Ellison, D.W, Gilbertson, R.J. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457, 603-607. [CrossRef] [PubMed]
71. Karbanova, J, Missol-Kolka, E, Fonseca, A.V, Lorra, C, Janich, P, Hollerova, H, Jaszai, J, Ehrmann, J, Kolar, Z, Liebers, C, et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J. Histochem. Cytochem. 2008, 56, 977-993. [CrossRef] [PubMed]
72. Irollo, E, Pirozzi, G. CD133: To be or not to be, is this the real question? Am. J. Transl. Res. 2013, 5, 563-581. [PubMed]
73. Yin, A.H, Miraglia, S, Zanjani, E.D, Almeida-Porada, G, Ogawa, M, Leary, A.G, Olweus, J, Kearney, J, Buck, D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90, 5002-5012. [PubMed]
74. Kemper, K, Sprick, M.R, de Bree, M, Scopelliti, A, Vermeulen, L, Hoek, M, Zeilstra, J, Pals, S.T, Mehmet, H, Stassi, G, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70, 719-729. [CrossRef] [PubMed]
75. Grosse-Gehling, P, Fargeas, C.A, Dittfeld, C, Garbe, Y, Alison, M.R, Corbeil, D, Kunz-Schughart, L.A. CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J. Pathol. 2013, 229, 355-378. [CrossRef] [PubMed]
76. Tirino, V, Camerlingo, R, Bifulco, K, Irollo, E, Montella, R, Paino, F, Sessa, G, Carriero, M.V, Normanno, N, Rocco, G, et al. TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell. Death Dis. 2013, 4, e620. [CrossRef] [PubMed]
77. O’Brien, C.A, Pollett, A, Gallinger, S, Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110. [CrossRef] [PubMed]
78. Swaminathan, S.K, Olin, M.R, Forster, C.L, Cruz, K.S, Panyam, J, Ohlfest, J.R. Identification of a novel monoclonal antibody recognizing CD133. J. Immunol. Methods 2010, 361, 110-115. [CrossRef] [PubMed]
79. Waldron, N.N, Kaufman, D.S, Oh, S, Inde, Z, Hexum, M.K, Ohlfest, J.R, Vallera, D.A. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011, 10, 1829-1838. [CrossRef] [PubMed]
80. Peichev, M, Naiyer, A.J, Pereira, D, Zhu, Z, Lane, W.J, Williams, M, Oz, M.C, Hicklin, D.J, Witte, L, Moore, M.A, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000, 95, 952-958. [PubMed]
81. Uchida, N, Buck, D.W, He, D, Reitsma, M.J, Masek, M, Phan, T.V, Tsukamoto, A.S, Gage, F.H, Weissman, I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA 2000, 97, 14720-14725. [CrossRef] [PubMed]
82. Smith, L.M, Nesterova, A, Ryan, M.C, Duniho, S, Jonas, M, Anderson, M, Zabinski, R.F, Sutherland, M.K, Gerber, H.P, Van Orden, K.L, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer. 2008, 99, 100-109. [CrossRef] [PubMed]
83. - cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J. Immunol. 2003, 171, 2977-2988. [CrossRef] [PubMed]
84. - peripheral blood mononuclear cells and their properties. Cardiovasc. Res. 2006, 70, 126-135. [CrossRef] [PubMed]
85. Zhao, Y, Glesne, D, Huberman, E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc. Natl. Acad. Sci. USA 2003, 100, 2426-2431. [CrossRef] [PubMed]
86. Urbich, C, Heeschen, C, Aicher, A, Dernbach, E, Zeiher, A.M, Dimmeler, S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003, 108, 2511-2516. [CrossRef] [PubMed]
87. Chen, S, Zhang, Q, Wu, X, Schultz, P.G, Ding, S. Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc. 2004, 126, 410-411. [CrossRef] [PubMed]
88. Bouckenooghe, T, Vandewalle, B, Moerman, E, Danze, P.M, Lukowiak, B, Muharram, G, Kerr-Conte, J, Gmyr, V, Laine, B, Pattou, F. Expression of progenitor cell markers during expansion of sorted human pancreatic beta cells. Gene Expr. 2005, 12, 83-98. [CrossRef] [PubMed]
89. Quirici, N, Soligo, D, Caneva, L, Servida, F, Bossolasco, P, Deliliers, G.L. Differentiation and expansion of endothelial cells from human bone marrow CD133+ cells. Br. J. Haematol. 2001, 115, 186-194. [CrossRef] [PubMed]
90. Donovan, L.K, Pilkington, G.J. CD133: Holy of grail of neuro-oncology or promiscuous red-herring? Cell. Prolif. 2012, 45, 527-537. [CrossRef] [PubMed]
91. Dubreuil, V, Marzesco, A.M, Corbeil, D, Huttner, W.B, Wilsch-Brauninger, M. Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. J. Cell. Biol. 2007, 176, 483-495. [CrossRef] [PubMed]
92. A.R. Jones, E.V.S. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 2007, 24, 1759-1771. [CrossRef] [PubMed]
93. Lichota, J, Skjorringe, T, Thomsen, L.B, Moos, T. Macromolecular drug transport into the brain using targeted therapy. J. Neurochem. 2010, 113, 1-13. [CrossRef] [PubMed]
94. Yu, Y.J, Watts, R.J. Developing Therapeutic Antibodies for Neurodegenerative Disease. Neurotherapeutics 2013, 10, 459-472. [CrossRef] [PubMed]
95. Gehling, U.M, Ergun, S, Schumacher, U, Wagener, C, Pantel, K, Otte, M, Schuch, G, Schafhausen, P, Mende, T, Kilic, N, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000, 95, 3106-3112. [CrossRef]
96. Adini, A, Adini, I, Ghosh, K, Benny, O, Pravda, E, Hu, R, Luyindula, D, D’Amato, R.J. The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action. Angiogenesis 2013, 16, 405-416. [CrossRef] [PubMed]
97. Jang, S.H, Wientjes, M.G, Lu, D, Au, J.L.S. Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20, 1337-1350. [CrossRef] [PubMed]
98. Petersdorf, S.H, Kopecky, K.J, Slovak, M, Willman, C, Nevill, T, Brandwein, J, Larson, R.A, Erba, H.P, Stiff, P.J, Stuart, R.K, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121, 4854-4860. [CrossRef] [PubMed]
99. Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S, Noppeney, R, Viardot, A, Hess, G, Schuler, M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321, 974-977. [CrossRef] [PubMed]
100. Le Jeune, C, Thomas, X. Potential for bispecific T-cell engagers: Role of blinatumomab in acute lymphoblastic leukemia. Drug Des. Devel. Ther. 2016, 10, 757-765. [PubMed]
101. Topp, M.S, Kufer, P, Gokbuget, N, Goebeler, M, Klinger, M, Neumann, S, Horst, H.A, Raff, T, Viardot, A, Schmid, M, et al. Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. J. Clin. Oncol. 2011, 29, 2493-2498. [CrossRef] [PubMed]
102. Ohlfest, J.R, Zellmer, D.M, Panyam, J, Swaminathan, S.K, Oh, S, Waldron, N.N, Toma, S, Vallera, D.A. Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv. Transl. Res. 2012, 3, 195-204. [CrossRef] [PubMed]
103. Waldron, N.N, Barsky, S.H, Dougherty, P.R, Vallera, D.A. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target. Oncol. 2014, 9, 239-249. [CrossRef] [PubMed]
104. Swaminathan, S.K, Roger, E, Toti, U, Niu, L, Ohlfest, J.R, Panyam, J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Control. Release 2013, 171, 280-287. [CrossRef] [PubMed]
105. Schmohl, J.U, Gleason, M.K, Dougherty, P.R, Miller, J.S, Vallera, D.A. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target. Oncol. 2015, 14, 1-9. [CrossRef] [PubMed]
106. Zhao, L, Yang, Y, Zhou, P, Ma, H, Zhao, X, He, X, Wang, T, Zhang, J, Liu, Y, Zhang, T. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody. J. Immunother. 2015, 38, 217-228. [CrossRef] [PubMed]
107. Huang, J, Li, C, Wang, Y, Lv, H, Guo, Y, Dai, H, Wicha, M.S, Chang, A.E, Li, Q. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin. Immunol. 2013, 149, 156-168. [CrossRef] [PubMed]
108. Swaminathan, S.K, Niu, L, Waldron, N, Kalscheuer, S, Zellmer, D.M, Olin, M.R, Ohlfest, J.R, Vallera, D.A, Panyam, J. Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv. Transl. Res. 2013, 3, 143-151. [CrossRef] [PubMed]
109. Kreitman, R.J, Pastan, I. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998, 58, 968-975. [PubMed]
110. Pastan, I, Chaudhary, V, FitzGerald, D.J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 1992, 61, 331-354. [CrossRef] [PubMed]
111. Kreitman, R.J, Pastan, I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 1995, 307, 29-37. [CrossRef] [PubMed]
112. Ohlfest, J.R, Zellmer, D.M, Panyam, J, Swaminathan, S.K, Oh, S, Waldron, N.N, Toma, S, Vallera, D.A. Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv. Transl. Res. 2013, 3, 195-204. [CrossRef] [PubMed]
113. Trzpis, M, McLaughlin, P.M, de Leij, L.M, Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395. [CrossRef] [PubMed]
114. Munz, M, Baeuerle, P.A, Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009, 69, 5627-5629. [CrossRef] [PubMed]
115. van der Gun, B.T, Melchers, L.J, Ruiters, M.H, de Leij, L.F, McLaughlin, P.M, Rots, M.G. EpCAM in carcinogenesis: The good, the bad or the ugly. Carcinogenesis 2010, 31, 1913-1921. [CrossRef] [PubMed]
116. Visvader, J.E, Lindeman, G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer. 2008, 8, 755-768. [CrossRef] [PubMed]
117. Shaw, F.L, Harrison, H, Spence, K, Ablett, M.P, Simoes, B.M, Farnie, G, Clarke, R.B. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia. 2012, 17, 111-117. [CrossRef] [PubMed]
118. Huehls, A.M, Coupet, T.A, Sentman, C.L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell. Biol. 2015, 93, 290-296. [CrossRef] [PubMed]
119. Topp, M.S, Gokbuget, N, Zugmaier, G, Klappers, P, Stelljes, M, Neumann, S, Viardot, A, Marks, R, Diedrich, H, Faul, C, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 2014, 32, 4134-4140. [CrossRef] [PubMed]
120. Berek, J.S, Edwards, R.P, Parker, L.P, DeMars, L.R, Herzog, T.J, Lentz, S.S, Morris, R.T, Akerley, W.L, Holloway, R.W, Method, M.W, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. Int. J. Gynecological cancer 2014, 24, 1583-1589. [CrossRef] [PubMed]
121. Arumugam, T, Simeone, D.M, Van Golen, K, Logsdon, C.D. S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 2005, 11, 5356-5364. [CrossRef] [PubMed]
122. Jiang, H, Hu, H, Tong, X, Jiang, Q, Zhu, H, Zhang, S. Calcium-binding protein S100P and cancer: Mechanisms and clinical relevance. J. Cancer Res. Clin. Oncol. 2012, 138, 1-9. [CrossRef] [PubMed]
123. Papadakis, K.A, Prehn, J.L, Landers, C, Han, Q, Luo, X, Cha, S.C, Wei, P, Targan, S.R. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J. Immunol. 2004, 172, 7002-7007. [CrossRef] [PubMed]
124. Vallera, D.A, Zhang, B, Gleason, M.K, Oh, S, Weiner, L.M, Kaufman, D.S, McCullar, V, Miller, J.S, Verneris, M.R. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 2013, 28, 274-282. [CrossRef] [PubMed]
125. Ranson, T, Vosshenrich, C.A, Corcuff, E, Richard, O, Muller, W, Di, S. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003, 101, 4887-4893. [CrossRef] [PubMed]
126. Huntington, N.D, Legrand, N, Alves, N.L, Jaron, B, Weijer, K, Plet, A, Corcuff, E, Mortier, E, Jacques, Y, Spits, H, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 2009, 206, 25-34. [CrossRef] [PubMed]
127. Waldmann, T.A. Interleukin-15 in the treatment of cancer. Expert Rev. Clin. Immunol. 2014, 10, 1689-1701. [CrossRef] [PubMed]
128. Basak, G.W, Zapala, L, Wysocki, P.J, Mackiewicz, A, Jakobisiak, M, Lasek, W. Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol. Rep. 2008, 19, 1173-1179. [CrossRef] [PubMed]
129. Schmohl, J.U, Felices, M, Taras, E, Miller, J.S, Vallera, D.A. Enhanced ADCC and NK cell activation of an anti-carcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol. Ther. 2016. in press. [CrossRef] [PubMed]
130. Munger, W, DeJoy, S.Q, Jeyaseelan, R., Torley, L.W, Grabstein, K.H, Eisenmann, J, Paxton, R, Cox, T, Wick, M.M, Kerwar, S.S. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2. Cell. Immunol. 1995, 165, 289-293. [CrossRef] [PubMed]
131. Vallera, D.A, Felices, M, McElmurry, R.T, McCullar, V, Zhou, X, Schmohl, J, Zhang, B, Lenvik, A, Panoskaltsis-Mortari, A, Verneris, M.R, et al. IL-15 Trispecific Killer Engagers (TriKEs) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing In Vivo Expansion, and Enhanced Function. Clin. Cancer Res. 2016. [CrossRef] [PubMed]
132. Ellington, A.D, Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822. [CrossRef] [PubMed]
133. Tuerk, C, Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510. [CrossRef] [PubMed]
134. Shigdar, S, Ward, A.C, De, A, Yang, C.J, Wei, M, Duan, W. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br. J. Haematol. 2011, 155, 3-13. [CrossRef] [PubMed]
135. Orava, E.W, Cicmil, N, Gariepy, J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim. Biophys. Acta 2010, 1798, 2190-2200. [CrossRef] [PubMed]
136. Shigdar, S, Qiao, L, Zhou, S.F, Xiang, D, Wang, T, Li, Y, Lim, L.Y, Kong, L, Li, L, Duan, W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330, 84-95. [CrossRef] [PubMed]